Current and emerging investigational medical therapies for the treatment of overactive bladder

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21:167-178.
   PubMed Web of Science ®Google Scholar
• BROWN JS, McGHAN WF, CHOKROVERTY S: Comorbidities associated with overactive bladder. Am. J. Manag. Care (2000) 6:S574-S579 (Supplement).
   PubMed Web of Science ®Google Scholar
• ABRAMS P, CARDOZO L, FALL M et al.: The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology (2003) 61:37-49.
   PubMed Web of Science ®Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 87:760-766.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20:327-336.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, BLAIVAS JG, STANTON SL, ANDERSEN JT: The standardisation of terminology of lower urinary tract function. Scand. J. Urol. Nephrol. (1988) 114:5-19.
   Google Scholar
• ABRAMS P, KELLEHER CJ, KERR LA, ROGERS RG: Overactive bladder significantly affects quality of life. Am. J. Manag. Care (2000) 6:S580-590 (Supplement).
   PubMed Web of Science ®Google Scholar
• YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. J. Urol. (2002) 168:1897-1913.
   PubMed Web of Science ®Google Scholar
• ELLIOTT DS, BOONE TB: Recent advances in the management of the neurogenic bladder. Urology (2000) 56(6 Suppl. 1):76-81
   PubMedGoogle Scholar
• TUBARO A: Defining overactive bladder: epidemiology and burden of disease. Urology (2004) 64(6 Suppl. 1):2-6.
   PubMed Web of Science ®Google Scholar
• EPSTEIN LB, GOLDBERG RP: The overactive bladder and quality of life. Int. J. Fertil. Women Med. (2005) 50:30-36.
   PubMed Web of Science ®Google Scholar
• HU-T, WAGNER TH, BENTKOVER JD et al.: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61:1123-1128.
   PubMed Web of Science ®Google Scholar
• HU-T, WAGNER TH: Health-related consequences of overactive bladder: An economic perspective. BJU Int. (2005) 96(Suppl. 1):43-45.
   PubMedGoogle Scholar
• BURGIO KL, LOCHER JL, GOODE PS et al.: Behavioral versus drug treatment for urge urinary incontinence in older women: a randomized controlled trial. J. Am. Med. Assoc. (1998) 280:1995-2000.
   PubMed Web of Science ®Google Scholar
• BURGIO KL, LOCHER JL, GOODE PS et al.: Combined behavioral and drug therapy for the treatment of urge incontinence in older women. J. Am. Geriatr. Soc. (2000) 48(4):370-374.
   PubMed Web of Science ®Google Scholar
• KNAPP PM: Identifying and treating urinary incontinence – the crucial role of the primary care physician. Postgrad. Med. (1998) 103:279-294.
   PubMed Web of Science ®Google Scholar
• WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther. (1995) 273:959-966.
   PubMed Web of Science ®Google Scholar
• YAMANISHI T, CHAPPLE CR, YASUDA K, CHESS-WILLIAMS R: The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br. J. Pharmacol. (2000) 131(7):1482-1488.
   PubMed Web of Science ®Google Scholar
• SELLERS DJ, YAMANISHI T, CHAPPLE CR et al.: M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J. Auton. Pharmacol. (2000) 20(3):171-176.
   PubMedGoogle Scholar
• YAMANISHI T, CHAPPLE CR, YASUDA K et al.: The role of M2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M3 inactivation. J. Urol. (2002) 167(1):397-401.
   PubMed Web of Science ®Google Scholar
• FETSCHER C, FLEICHMAN M, SCHMIDT M et al.: M3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. (2002) 136(5):641-643.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, FREEMAN R, ANDERSTRÖM C et al.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. BJU Int. (1998) 81:801-810.
   Google Scholar
• MATSUI M, MOTOMURA D, FUJIKAWA T et al.: Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci. (2002) 22:10627-10632.
   PubMed Web of Science ®Google Scholar
• EHLERT FJ, GRIFFIN MT, ABE DM et al.: The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J. Pharmacol. Exp. Ther. (2005) 313:368-378.
   PubMed Web of Science ®Google Scholar
• DIOKNO AC, APPELL RA, SAND PK et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. (2003) 78:687-695.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, MARTINEZ-GARCIA R, SELVAGGI L et al.: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. (2005) 48:464-470.
   PubMed Web of Science ®Google Scholar
• PORTERA SG, LIPSCOMB GH: Pharmacologic therapy for urinary incontinence and voiding dysfunction. Clin. Obstet. Gynecol. (1998) 41:691-701.
   PubMed Web of Science ®Google Scholar
• ABRAMOV Y, SAND PK: Oxybutyinin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin. Pharmacother. (2004) 5(11):2351-2359.
   PubMed Web of Science ®Google Scholar
• SATHYAN D, CHANCELLOR M, GUPTA S: Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br. J. Clin. Pharmacol. (2001) 51:409-417.
   Web of Science ®Google Scholar
• COMER AM, GOA KL: Extended-release oxybutynin. Drugs Aging (2000) 16:149.
   PubMed Web of Science ®Google Scholar
• GUPTA S, SATHYAN G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol. (1999) 39:289-296.
   PubMed Web of Science ®Google Scholar
• APPELL R, CHANCELLOR M, ZOBRIST H et al.: Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. (2003) 78:696-702.
   PubMed Web of Science ®Google Scholar
• ANDERSON RU, MOBLEY D, BLANK B, SALTZSTEIN D, SUSSET J, BROWN JS: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol. (1999) 161:1809-1812.
   PubMed Web of Science ®Google Scholar
• GLEASON DM, SUSSET J, WHITE C, MUNOZ DR, SAND PK: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology (1999) 54:420-423.
   PubMed Web of Science ®Google Scholar
• BIRNS J, LUKKARI E, MALONE-LEE JG: A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. Br. J. Urol. (2000) 85:793-798.
   Google Scholar
• BRENDLER CB, RADEBAUGH LC, MOHLER JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J. Urol. (1989) 141:1350-1352.
   PubMed Web of Science ®Google Scholar
• BOONE TB, APPELL RA, LOPEZ MA et al.: Pharmacokinetic evaluation of intravesical oxybutynin: bolus and continuous delivery. J. Urol. (2001) 165(Suppl.):252 (Abstract 1039).
   Google Scholar
• SAITO M, TABUCHI F, OTSUBO K, MIYAGAWA I: Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol. Urodyn. (2000) 19:683.
   PubMed Web of Science ®Google Scholar
• PANNAEK J, SOMMERFELD HJ, BOTEL U, SENGET T: Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology (2000) 55:358.
   PubMed Web of Science ®Google Scholar
• ENZELSBERGER H, HELMER H, KURZ CH: Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomized trial. Br. J. Obstet. Gynecol. (1995) 102:929-930.
   PubMedGoogle Scholar
• KASABIAN NG, VLACHIOTIS JD, LAIS A et al.: The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J. Urol. (1994) 151:944.
   PubMed Web of Science ®Google Scholar
• KAPLINSKY R, GREENFIELD S, WAN J, FERA M: Expanded follow-up of intravesical oxybutynin chloriden use in children with neurogenic bladder. J. Urol. (1996) 156:753.
   PubMed Web of Science ®Google Scholar
• PAINTER KA, VATES TS, BUKOWSKI TP et al.: Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J. Urol. (1996) 156:1459.
   PubMed Web of Science ®Google Scholar
• DMOCHOWSKI RR, DAVILA GW, ZINNER NR et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Urol. (2002) 168:580-586.
   PubMed Web of Science ®Google Scholar
• DAVILA GW, DAUGHERTY CA, SANDERS SW et al.: A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J. Urol. (2001) 166:140-145.
   PubMed Web of Science ®Google Scholar
• SCHRODER A, LEVIN R, KOGAN B et al.: Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology (2000) 56:1063-1067.
   PubMed Web of Science ®Google Scholar
• JONES SE, SHUBA LM, ZHABYEYEV P, McCULLOUGH JR, McDONALD TF: Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials. Br. J. Pharmacol. (2000) 131(2):245-254.
   PubMed Web of Science ®Google Scholar
• STAHL MM, EKSTROM B, SPARF B, MATTIASSON A, ANDERSON KE: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn. (1995) 14:647-655.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine – a new bladder selective antimuscarinic agent. Eur. J. Pharmacol. (1997) 327:195-207.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L, GILLBERG PG, SPARF B: Antimuscarinic potency and bladder selectivity of PNU200577, a major metabolite of tolterodine. Pharmacol. Toxicol. (1997) 81:169-172.
   PubMedGoogle Scholar
• STAHL MM, EKSTROM B, SPARF B, MATTISSON A, ANDERSSON KE: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn. (1995) 14:647-655.
   PubMed Web of Science ®Google Scholar
• BRYNNE N, STAHL MMS, HALLÉN B et al.: Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int. J. Clin. Pharmacol. Ther. (1997) 35:287-295.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK P, KREDER K, JONAS U, ZINNER N, WEIN A ON BEHALF OF THE TOLETRODINE STUDY GROUP: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology (2001) 57:414-421.
   PubMed Web of Science ®Google Scholar
• HOMMA Y, PAICK JS, LEE JG, KAWABE K: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. (2003) 92:741-747.
   PubMed Web of Science ®Google Scholar
• GARLEY AD, BURROWS LJ: Current pharmacotherapeutic strategies for overactive bladder. Expert Opin. Pharmacother. (2002) 3(7):827-833.
   PubMedGoogle Scholar
• APPELL RA, SAND P, DMOCHOWSKI R et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartarate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin. Proc. (2001) 76:358-363.
   PubMed Web of Science ®Google Scholar
• RACKLEY R, WEIN A, NELSON D: Medical treatment of overactive bladder. Mayo Clin. Proc. (2001) 76(11):1179-1180.
   PubMedGoogle Scholar
• SUSSMAN D, GARELY A: Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr. Med. Res. Opin. (2002) 18:177-84.
   PubMed Web of Science ®Google Scholar
• NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Urodyn. (2001) 20(4):A445 (Abstract).
   Google Scholar
• NEWGREEN DT, NAYLOR AM: Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutynin. Br. J. Pharmacol. (1996) 117(Suppl.):107P (Abstract).
   Web of Science ®Google Scholar
• WILLIAMSON IJR, NEWGREEN DT, NAYLOR AM: The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat. Br. J. Pharmacol. (1997) 120(Suppl.):205P (Abstract).
   Web of Science ®Google Scholar
• DAVIES CL, DODD MG, MERNER PA, RANKIN AJ: In vivo bladder selectivity of the novel muscarinic antagonist, darifenacin, in the conscious minipig. Br. J. Pharmacol. (1996) 117(Suppl.):202P (Abstract).
   Web of Science ®Google Scholar
• HAAB F: Darifenacin in the treatment of overactive bladder. Drugs Today (2005) 41(7):441-452.
   PubMed Web of Science ®Google Scholar
• IKEDA K: Affinity of YM905 for human muscarinic M1, M2 and M3 receptors. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803214-02.00. International Study ID:905-PH-002.
   Google Scholar
• IKEDA K, KOBAYASHI S: Effects of YM905, tolterodine and oxybutynin on M3 receptor mediated cytosolic Ca2+ mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803217-02.000. International Study ID:905-PH-005.
   Google Scholar
• ROBINSON D, CARDOZO L: The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin. Invest. Drugs (2004) 13(10):1339-1348.
   PubMed Web of Science ®Google Scholar
• ZINNER NR: Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin. Pharmacother. (2005) 6(8):1409-1420.
   PubMed Web of Science ®Google Scholar
• SANCTURA: Trospium chloride tablets. Prescribing information, USA (2004).
   Google Scholar
• WILLIAMS RC: Potential therapeutic targets for the treatment of detrusor overactivity. Expert Opin. Ther. Targets (2004) 8(2):95-106.
   PubMed Web of Science ®Google Scholar
• McCONELL J, BENSON GS, WOOD JG: Autonomic innervation of the urogenital system: adrenergic and cholinergic elements. Brain Res. Bull. (1982) 9:679-694.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev. (1993) 45:254-308.
   Google Scholar
• AWAD SA, BRUCE AW, CARRO-CIAMPI G et al.: Distribution of α- and β-adrenoceptors in human urinary bladder. Br. J. Pharmacol. (1974) 50:525-529.
   PubMed Web of Science ®Google Scholar
• LEVIN RM, SHOFER FS, WEIN AJ: Cholinergic, adrenergic and purinergic response of sequential strips of rabbit urinary bladder. J. Pharmacol. Exp. Ther. (1980) 212(3):536-540.
   PubMed Web of Science ®Google Scholar
• WEIN AJ: Neuromuscular dysfunction of the lower urinary tract. In: Campbell’s urology, (Edition 6), WB Saunders, Philadelphia, USA (1994) 1:573-642.
   Google Scholar
• LEVIN RM, RUGGERI MR, WEIN AJ: Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. J. Urol. (1988) 139:844-848.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI O: β3-adrenoceptors in human detrusor muscle. Urology (2002) 59(5 Suppl. 1):25-29.
   PubMed Web of Science ®Google Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: The role of β3-adrenoceptors in normal and neurogenic detrusors. (Proceedings of 1997 ICS annual meeting, Abstract 14). Neurourol. Urodyn. (1997) 16:363-365.
   Google Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: Possible β3-adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol. Scand. (1998) 164:117-118.
   PubMedGoogle Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. (1999) 126:819-825.
   PubMed Web of Science ®Google Scholar
• TAKEDA M, OBARA K, MIZUSAWA T et al.: Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. (1999) 288:1367-1373.
   PubMed Web of Science ®Google Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: Relaxant effects of isoproterenol and selective β3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J. Urol. (2001) 165:240-244.
   PubMed Web of Science ®Google Scholar
• TAKEDA H, IGAWA Y, KOMATSU Y et al.: Characterization of β-adrenoceptor subtypes in the ferret urinary bladder in vitro and in vivo. Eur. J. Pharmacol. (2000) 403:147-155.
   PubMed Web of Science ®Google Scholar
• TAKEDA H, YAMAZAKI Y, AKAHANE M et al.: Characterization of β-adrenoceptor subtype in bladder smooth muscle in cynomolgus monkey. Jpn J. Pharmacol. (2002) 8:108-113.
   Google Scholar
• TAKEDA H, YAMAZAKI Y, IGAWA Y et al.: Effects of β3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol. Urodyn. (2002) 21:558-565.
   PubMed Web of Science ®Google Scholar
• KAIDOH K, IGAWA Y, TAKEDA H et al.: Effects of selective β2 and β3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J. Urol. (2002) 168:1247-1252.
   PubMed Web of Science ®Google Scholar
• TANAKA N, TAMAI T, MUKAIYAMA H et al.: β3-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence: 2-[4-(2-[[(1S,2R)-2- hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid. Bioorg. Med. Chem. (2001) 9:3265-3271.
   PubMed Web of Science ®Google Scholar
• TANAKA N, TAMAI T, MUKAIYAMA H et al. Discovery of novel N-phenylglycine derivatives as potent and selective β3-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence. J. Med. Chem. (2001) 44:1436-1445.
   PubMed Web of Science ®Google Scholar
• TANAKA N, TAMAI T, MUKAIYAMA H et al.: Relationship between stereochemistry and the β3-adrenoceptor agonistic activity of 4′-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. J. Med. Chem. (2003) 46:105-112.
   PubMed Web of Science ®Google Scholar
• WIBBERLY A, WESTFALL TD, RIEDEL ES et al.: GW427353 (solabegron), a β-3 adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. Abstracts of the American Urological Association, Texas, USA (2005).
   Google Scholar
• DYKSTRA DD, SIDI AA, SCOTT AB et al.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. (1988) 139:919.
   PubMed Web of Science ®Google Scholar
• SCHURCH B, STOHRER M, KRAMER G et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. (2000) 164:692-697.
   PubMed Web of Science ®Google Scholar
• CHANCELLOR MB, O’LEARY M, ERICKSON J et al.: Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J. Urol. (2003) 169(Suppl.):351 (Abstract DP50).
   Google Scholar
• MAAN Z, SINGARY WA, SHERGILL I et al.: Alternative use of botulinum toxin in urology. Expert Opin. Pharmacother. (2004) 5(5):1015-1021.
   PubMed Web of Science ®Google Scholar
• REITZ A, STOHRER M, KRAMER G et al.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur. Urol. (2004) 45:510-515.
   PubMed Web of Science ®Google Scholar
• HAJEBRAHIMI S, ALTAWEEL W, CADORET J et al.: Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can. J. Urol. (2005) 12:2543-2546.
   PubMedGoogle Scholar
• RAJKUMAR GN, SMALL DR, MUSTAFA AW, CONN G: A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. (2006) 96:848-852.
   Web of Science ®Google Scholar
• GOPALAKRISHNAN M, SHIEH CC: Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin. Ther. Targets (2004) 8(5):437-458.
   PubMed Web of Science ®Google Scholar
• SHYNG S, NICHOLS CG: Octameric stoichiometry of the KATP channel complex. J. Gen. Physiol. (1997) 110:655-664.
   PubMed Web of Science ®Google Scholar
• YAMADA M, ISOMOTO S, MATSUMOTO S et al.: Sulphonylurea receptor 2B and Kir 6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel. J. Physiol. (1997) 499:715-720.
   PubMed Web of Science ®Google Scholar
• ISOMOTO S, KONDO C, YAMADA M et al.: A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J. Biol. Chem. (1996) 271:24321-24324.
   PubMed Web of Science ®Google Scholar
• GOPALAKRISHNAN M, WHITEAKER KL, MOLINARI EJ et al.: Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells. J. Pharmacol. Exp. Ther. (1999) 289:551-558.
   PubMed Web of Science ®Google Scholar
• DAVIS-TABER R, CHOI W, FENG J et al.: Molecular characterization of human SUR2-containing KATP channels. Gene (2000) 256:261-270.
   PubMed Web of Science ®Google Scholar
• SCOTT VE, DAVIS-TABER RA, SILVIA C et al.: Characterization of human urinary bladder KATP channels containing SUR2B splice variants expressed in L-cells. Eur. J. Pharmacol. (2004) 483:195-205.
   PubMed Web of Science ®Google Scholar
• HEPPNER TJ, BONEV A, LI JH, KAU ST, NELSON MT: Zeneca ZD6169 activates ATP-sensitive K+ channels in the urinary bladder of the guinea pig. Pharmacology (1996) 53:170-179.
   PubMed Web of Science ®Google Scholar
• HOWE BB, HALTERMAN TJ, YOCHIM CL et al.: ZENECA ZD6169: a novel KATP channel opener with an in vivo selectivity for urinary bladder. J. Pharmacol. Exp. Ther. (1995) 274:884-890.
   PubMed Web of Science ®Google Scholar
• TOMINAGA M, CATERINA MJ, MALMBERG AB et al.: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron (1998) 21:531-543.
   PubMed Web of Science ®Google Scholar
• GUO A, VULCHANOVA L, WANG J, LI X, ELDE R: Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci. (1999) 11:946-958.
   PubMed Web of Science ®Google Scholar
• MICHAEL GJ, PRIESTLEY JV. Differential expression of the mRNA for the vanilloid receptor subtype 1 in cells of the adult rat dorsal root and no dose ganglia and its downregulation by axotomy. J. Neurosci. (1999) 19:1844-1854.
   PubMed Web of Science ®Google Scholar
• OST D, ROSKAMS T, VAN DER AA F, DE RIDDER D: Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J. Urol. (2002) 168:293-297.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Bladder activation: afferent mechanisms. Urology (2002) 59:43-50.
   PubMed Web of Science ®Google Scholar
• BIRDER LA, NAKAMURA Y, KISS S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci. (2002) 5:856-860.
   PubMed Web of Science ®Google Scholar
• BRADY CM, APOSTOLIDIS AN, HARPER M et al.: Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. (2004) 93:770-776.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC, KAWATANI M, HISAMITSU T et al.: Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. (1990) 30(Suppl.):S71-S77.
   PubMedGoogle Scholar
• LYNN B: Capsaicin: actions on C fibre afferents that may be involved in itch. Skin Pharmacol. (1992) 5:9-13.
   PubMedGoogle Scholar
• DASGUPTA P, CHANDIRAMANI VA, BECKETT A, SCARAVILLI F, FOWLER CJ: The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJU Int. (2000) 85(3):238-245.
   PubMed Web of Science ®Google Scholar
• MEZEY E, TOTH ZE, CORTRIGHT DN et al.: Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. USA (2000) 97:3655-3660.
   PubMed Web of Science ®Google Scholar
• SZALLASI A: Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man. Acta Physiol. Scand. (1995) 629(Suppl.):1-68.
   Google Scholar
• YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. J. Urol. (2002) 168(5):1897-1913.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC, YOSHIMURA N: Pharmacology of the lower urinary tract. Ann. Rev. Pharmacol. Toxicol. (2001) 41:691-721.
   PubMed Web of Science ®Google Scholar
• SZALLASI A, BLUMBERG PM: Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci. (1990) 16:1399-1408.
   Google Scholar
• RAISINGHANI M, PABBIDI RM, PREMKUMAR LS: Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin. J. Physiol. (2005) 567:771-786.
   PubMed Web of Science ®Google Scholar
• PALMA PC, THIEL M, RICCETTO CL et al.: Resiniferatoxin for detrusor instability refractory to anticholinergics. Int. Braz. J. Urol. (2004) 30:53-58.
   PubMedGoogle Scholar
• GIANNANTONI A, DI STASSI SM, STEPHEN RL et al.: Intravesical rsiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J. Urol. (2004) 172:240-243.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC: Influence of central serotonergic mechanisms on lower urinary tract function. Urology (2002) 59(Suppl. 5A):30-36.
   PubMed Web of Science ®Google Scholar
• TESTA RL, GUARNERI E, POGGESI P et al.: Effects of several 5-hydroxytryptamine1A receptor ligands on the micturition reflex in rats: comparison with WAY 100635. J. Pharmacol. Exp. Ther. (1999) 290:1258-1269.
   PubMed Web of Science ®Google Scholar
• KAKIZAKI H, YOSHIYAMA M, KOYANAGI T et al.: Effect of WAY100635, a selective 5-HT1A-receptor antagonist on the micturition-reflex pathway in the rat. Am. J. Physiol. (2001) 280:R1407-R1413.
   Web of Science ®Google Scholar
• DARBLADE B, BEHR-ROUSSEL D, GORNY D et al.: Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle. World J. Urol. (2005) 23(2):147-151.
   PubMed Web of Science ®Google Scholar
• D’AGOSTINO G, CONDINO AM, GALLINARI P, FRANCESCHETTI GP, TONINI M: Characterization of prejunctional serotonin receptors modulating [3H] acetylcholine release in the human detrusor. J. Pharmacol. Exp. Ther. (2006) 316(1):129-135.
   PubMed Web of Science ®Google Scholar
• FORD AP, GEVER JR, NUNN PA et al.: Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br. J. Pharmacol. (2006) 147(Suppl. 2):S132-S143.
   PubMed Web of Science ®Google Scholar
• BURNSTOCK G: Purinergic nerves. Pharmacol. Rev. (1972) 24(3):509-581.
   PubMed Web of Science ®Google Scholar
• FUJII K: Evidence for adenosine triphosphate as an excitatory transmitter in guinea-pig, rabbit and pig urinary bladder. J. Physiol. (1988) 404:39-52.
   PubMed Web of Science ®Google Scholar
• BURNSTOCK G: Noradrenaline and ATP: cotransmitters and neuromodulators. J. Physiol. Pharmacol. (1995) 46(4):365-384.
   PubMed Web of Science ®Google Scholar
• McMURRAY G, DASS N, BRADING AF: Purinoceptor subtypes mediating contraction and relaxation of marmoset urinary bladder smooth muscle. Br. J. Pharmacol. (1998) 123:1579-1586.
   PubMed Web of Science ®Google Scholar
• FERGUSON DR, KENNEDY I, BURTON TJ: ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes – a possible sensory mechanism? J. Physiol. (1997) 505:503-511.
   PubMed Web of Science ®Google Scholar
• RAPP DE, LYON MB, BALES GT, COOK SP: A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur. Urol. (2005) 48(2):303-308.
   PubMed Web of Science ®Google Scholar
• HUA XY, THEODORSSON-NORHEIM E, LUNDBERG JM et al.: Co-localization of tachykinins and calcitonin gene-related peptide in capsaicin-sensitive afferents in relation to motility effects on the human ureter in vitro. Neuroscience (1987) 23(2):693-703.
   PubMed Web of Science ®Google Scholar
• REGOLI D, BOUDON A, FAUCHERE JL: Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. (1994) 46(4):551-599.
   PubMed Web of Science ®Google Scholar
• GUARD S, McKNIGHT AT, WATLING KJ, WATSON SP: Evidence for two types of tachykinin receptors on cholinergic neurons of the guinea pig ileum myenteric plexus. Ann. NY Acad. Sci. (1991) 632:400-403.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, PATACCHINI R, ROVERO P, GIACHETTI A: Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. (1993) 13(1):23-93.
   PubMedGoogle Scholar
• NAKANISHI S: Mammalian tachykinin receptors. Ann. Rev. Neurosci. (1991) 14:123-136.
   PubMed Web of Science ®Google Scholar
• WIESENFELD-HALLIN Z, HOKFELT T, LUNDBERG JM et al.: Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat. Neurosci. Lett. (1984) 52:199-204.
   PubMed Web of Science ®Google Scholar
• JESSELL TM: Cellular interactions at the central and peripheral terminals of primary sensory neurons. J. Immunol. (1985) 135(Suppl. 2):746s-749s.
   PubMed Web of Science ®Google Scholar
• MICEVYCH PE, KRUGER L: The status of calcitonin gene-related peptide as an effector peptide. Ann. NY Acad. Sci. (1992) 657:379-396.
   PubMed Web of Science ®Google Scholar
• WEIHE E: Neurochemical anatomy of the mammalian spinal cord: functional implications. Ann. Anat. (1992) 174:89-118.
   PubMed Web of Science ®Google Scholar
• MANTYH PW, ROGERS SD, HONORE P et al.: Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 278:275-279.
   PubMed Web of Science ®Google Scholar
• KURAISHI Y, HIROTA N, SATO Y et al.: Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. (1985) 325:294-298.
   PubMed Web of Science ®Google Scholar
• ANDERSSON PO, ANDERSSON KE, FAHRENKRUG J et al.: Contents and effects of substance P and vasoactive intestinal polypeptide in the bladder of rats with and without infravesical outflow obstruction. J. Urol. (1988) 140:168-172.
   PubMed Web of Science ®Google Scholar
• CROWE R, VALE J, TROTT KR et al.: Radiation-induced changes in neuropeptides in the rat urinary bladder. J. Urol. (1996) 156:2062-2066.
   PubMed Web of Science ®Google Scholar
• SHAKER HS, TU LM, KALFOPOULOS M et al.: Hyperreflexia of the urinary bladder: possible role of the efferent function of the capsaicin sensitive primary afferents. J. Urol. (1998) 160:2232-2239.
   PubMed Web of Science ®Google Scholar
• LECCI A, GIULIANI S, PATACCHINI R, MAGGI CA: Evidence against a peripheral role of tachykinins in the initiation of micturition reflex in rats. J. Pharmacol. Exp. Ther. (1993) 264:1327-1332.
   PubMed Web of Science ®Google Scholar
• ISHIZUKA O, MATTIASSON A, ANDERSSON KE: Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J. Urol. (1995) 153:2034-2038.
   PubMed Web of Science ®Google Scholar
• DOI T, KAMO I, IMAI S et al.: Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig. Eur. J. Pharmacol. (1999) 383:297-303.
   PubMed Web of Science ®Google Scholar
• BURCHER E, ZENG XP, STRIGAS J et al.: Autoradiographic localization of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder. J. Urol. (2000) 163:331-337.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, SANTICIOLI P, PATACCHINI R et al.: Contractile response of the human isolated urinary bladder to neurokinins: involvement of NK-2 receptors. Eur. J. Pharmacol. (1988) 145:335-340.
   PubMed Web of Science ®Google Scholar
• LECCI A, MAGGI CA: Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul. Pept. (2001) 101:1-18.
   PubMed Web of Science ®Google Scholar
• ABDEL-GAWAD M, DION SB, ELHILALI MM: Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. J. Urol. (2001) 165:1739-1744.
   PubMed Web of Science ®Google Scholar
• BALLET S, AUBEL B, MAUBORGNE A et al.: The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology (2001) 40:578-589.
   PubMed Web of Science ®Google Scholar
• NISHINO Y, OGURA T, YAMADA T et al.: Assessment of two α1 adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, on voiding disturbance in benign prostatic hyperplasia patients, a randomized cross-over study. ICS Proceedings (2002):116.
   Google Scholar
• GOTOH M, KAMIHIRA O, KINUKAWA T et al.: Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int. (2005) 96:581-586.
   PubMed Web of Science ®Google Scholar
• TUTTLE JB, STEERS WD, ALBO M, NATALUK E: Neural input regulates tissue NGF and growth of the adult urinary bladder. J. Auton. Nerv. Syst. (1994) 49:147-158.
   PubMedGoogle Scholar
• STEERS WD, KOLBECK S, CREEDON D, TUTTLE JB: Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J. Clin. Invest. (1991) 88:1709-1715.
   PubMed Web of Science ®Google Scholar
• LOWE EM, ANAND P, TERENGHI G et al.: Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. (1997) 79:572-577.
   PubMedGoogle Scholar
• YOSHIMURA N, SEKI S, ERICKSON V et al.: Suppression of the tetrodotoxin-resistant sodium channel (PN3/SNS): a possible new treatment for bladder pain. Urology (2001) 57(Suppl. 1):116-117.
   Google Scholar
• GIANNANTONI A, DI STASI SM, NARDICCHI V et al.: Botulinum-A toxin injections in the detrusor muscle reduce nerve growth factor bladder tissue levels in patients affected by neurogenic detrusor overactivity. J. Urol. (2006) 175:2341-2344.
   PubMed Web of Science ®Google Scholar
• STEERS WD, TUTTLE JB: Mechanism of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Prac. Urol. (2006) 3:101-110.
   PubMedGoogle Scholar
• CHRIST GJ, DAY NS, DAY M et al.: Bladder injection of ‘naked’ hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281:R100-R109.
   Google Scholar
• CHANCELLOR MB: New frontiers in the treatment of overactive bladder and incontinence. Rev. Urol. (2002) 4(Suppl. 4):S50-S56.
   PubMedGoogle Scholar
• TIWARI A, KRISHNA NS, NANDA K, CHUGH A: Benign prostatic hyperplasia: an insight into current investigational medial therapies. Expert Opin. Invest. Drugs (2005) 14(11):1359-1372.
   PubMed Web of Science ®Google Scholar
• ATALA A: Creation of bladder tissue in vitro and in vivo: a system for organ replacement. Adv. Exp. Med. Biol. (1999) 462:31-42.
   PubMed Web of Science ®Google Scholar
• KOH CJ, ATALA A: Tissue engineering for urinary incontinence applications. Minerva Ginecol. (2004) 56:371-378.
   PubMedGoogle Scholar
• KIM YT, KWON DD, KIM J et al.: Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int. Braz. J. Urol. (2004) 30:275-278.
   PubMedGoogle Scholar